DEB-TACE + Lenvatinib

DEB-TACE + lenvatinib is a combination therapy used in the treatment of hepatocellular carcinoma (HCC). This treatment combines two distinct approaches: Drug-eluting bead transarterial chemoembolization (DEB-TACE) and the angiogenesis inhibitor lenvatinib. ## What is DEB-TACE? DEB-TACE is a minimally invasive procedure performed in interventional radiology to treat hypervascularized tumors, particularly HCC. It involves: 1. Using microspheres (beads) loaded with chemotherapy drugs (typically doxorubicin) 2. Delivering these beads directly to the tumor through catheterization of the arterial branch feeding the tumor 3. The beads both block blood supply to the tumor (embolization) and release chemotherapy locally over time[1][5][8] DEB-TACE differs from conventional TACE (cTACE) in that it uses drug-eluting beads rather than a mixture of chemotherapy with lipiodol followed by separate embolization agents[5]. This approach allows for more sustained local chemotherapy release while reducing systemic drug exposure[4][8]. ## What is Lenvatinib? Lenvatinib (brand name Lenvima) is an angiogenesis inhibitor - a targeted therapy that works by blocking the formation of new blood vessels that feed tumors[6]. ## The Combination Approach The LEAP-012 clinical trial tested DEB-TACE in combination with lenvatinib and the immunotherapy drug pembrolizumab (Keytruda) for intermediate-stage HCC. Results published in 2025 showed: - Patients treated with this triple combination lived longer without their cancer progressing compared to those treated with DEB-TACE alone - Median progression-free survival was 14.6 months for the combination versus 10 months for DEB-TACE alone[6] This combination approach represents an emerging treatment strategy for intermediate-stage HCC that cannot be surgically removed. The rationale appears to be that combining local therapy (DEB-TACE) with systemic therapies that target different aspects of cancer biology (angiogenesis inhibition with lenvatinib and immunotherapy) may provide superior outcomes compared to local therapy alone. While the results are promising, longer follow-up is needed to determine if this combination improves overall survival. Nevertheless, oncologists are expected to begin offering this treatment option to more patients with intermediate-stage HCC[6].